A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Different Extended Release Formulations of Tablets of AZD3241 (300 mg) After Administration of Multiple Doses in Healthy Male and Female Volunteers.
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2015
At a glance
- Drugs AZD 3241 (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- 16 Aug 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 23 Nov 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 26 Oct 2011 New trial record